Breaking News
September 23, 2018 - Removing tobacco product display from shops reduced number of children buying cigarettes
September 23, 2018 - Random fraction of specialized immune cells leads the charge in battling invaders
September 23, 2018 - Few minutes of sprinting exercise may be as effective as longer exercise sessions
September 23, 2018 - Researchers use neutrons to make first direct observations of water in lipid bilayers
September 23, 2018 - Researchers demonstrate pre-clinical success for universal flu vaccine in new paper
September 23, 2018 - Study reveals surprising gaps in some HIV medical providers’ knowledge of ACA
September 23, 2018 - Oxehealth secures European medical device accreditation for vital signs measurement software
September 23, 2018 - HTN Tx Intensification Common Upon Discharge in U.S. Vets
September 23, 2018 - Fibre can strengthen the intestinal barrier
September 23, 2018 - New platform examines infectious pathogens that may spread from animals to humans
September 23, 2018 - Demographers create detailed color map of population aging in Europe
September 23, 2018 - New type of fatty acid can slow down overreactive immune system
September 23, 2018 - Innovative procedure could provide breakthrough in treating early-stage lung cancer
September 23, 2018 - Research finds drop in number of measles cases in the EU/EEA since March 2018
September 23, 2018 - Researchers acquire new insights into DNA polymerases
September 23, 2018 - Alzheimer’s diagnosis might become simpler with new brain imaging method
September 23, 2018 - Reports Warn of Growing Opioid Crisis Among Seniors
September 23, 2018 - Researchers unravel why people with HIV suffer from more neurologic diseases
September 23, 2018 - Human brain structured to make best possible decision with limited resources
September 23, 2018 - KHN’s ‘What the Health?’ Health on the hill
September 23, 2018 - Bad air and inadequate data prove an unhealthy mix
September 23, 2018 - Regular bedtime and wake time important for heart, metabolic health even among adults
September 23, 2018 - HIV and a tale of a few cities
September 23, 2018 - NIH launches clinical trial to test infusions of combination antibodies in people with HIV
September 23, 2018 - Researchers develop new system to detect consumption of synthetic cannabinoids
September 23, 2018 - Vax-Hub to influenze radical change in development and manufacturing of vaccines
September 23, 2018 - People who have slept lesser than seven hours have higher risks of car crashes
September 23, 2018 - an ancient art may work best to prevent falls in old age
September 23, 2018 - Consumption of foods with lower nutritional quality related to increased cancer risk
September 23, 2018 - Patient Health Information Often Shared Electronically
September 23, 2018 - Can machine learning bring more humanity to health care?
September 23, 2018 - Body organs undergo structural changes in response to diet
September 23, 2018 - Genetic polymorphisms linked with muscle injury and stiffness
September 23, 2018 - As states try to rein in drug spending, feds slap down one bold Medicaid move
September 22, 2018 - Why Eczema Is Tougher to Treat for Black Patients
September 22, 2018 - Team reveals that human genome could contain up to 20 percent fewer genes
September 22, 2018 - USC research uncovers previously unknown genetic risk factor for Alzheimer’s disease
September 22, 2018 - Novel method achieves accurate and precise temperature estimation in fat-containing tissues
September 22, 2018 - BSI accredits Oxehealth’s vital signs measurement software as Class IIa medical device
September 22, 2018 - Evolution of psychiatric disorders and human personality traits
September 22, 2018 - Obesity in early puberty doubles asthma risk for boy’s future offspring
September 22, 2018 - World’s most advanced real-time patient monitoring platform receives key US patent
September 22, 2018 - Study explores connection between sexuality and cognitive status in older adults
September 22, 2018 - LSTM partners with TB Alliance to develop novel TB drug regimens
September 22, 2018 - Annual wellness visits improve delivery of preventive services in elderly population
September 22, 2018 - CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma
September 22, 2018 - Hispanic communities with high proportions of Hispanics face more cardiovascular-related death
September 22, 2018 - Vici syndrome – Genetics Home Reference
September 22, 2018 - Single-dose drug can shorten flu symptoms by about a day, studies suggest
September 22, 2018 - AMSBIO launches circulating tumor DNA Reference Standards
September 22, 2018 - Sandalwood mimicking odorant could stimulate hair growth in humans
September 22, 2018 - Overlooked immune cells could play a key role in cancer immunotherapy, claims new study
September 22, 2018 - Study reveals prevalence of diagnosed type 1 and type 2 diabetes among American adults
September 22, 2018 - Researchers develop fast detection strategy to know type of virus acquired by patients
September 22, 2018 - Global Prevalence of Insufficient Activity 27.5 Percent
September 22, 2018 - Strategies to protect bone health in hematologic stem cell transplant recipients
September 22, 2018 - Brigham Genomic Medicine program unravels 30 medical mysteries
September 22, 2018 - New system harnesses power of bubbles to destroy dangerous biofilms
September 22, 2018 - Inflammation plays crucial role in preventing heart attacks and strokes, study reveals
September 22, 2018 - Calorie dense, nutrient deficient meals common across the world
September 22, 2018 - Researchers develop technology to study behavior of implants without animal testing
September 22, 2018 - First gut bacteria in newborns may have lasting effect on ability to ward off chronic diseases
September 22, 2018 - Detection of BFD virus in parrots in 8 new countries raises concerns for threatened species
September 22, 2018 - Insulin treatment shows great potential against chronic bowel inflammation
September 22, 2018 - ‘Liking Gap’ Might Stand in Way of New Friendships
September 22, 2018 - Simple factors that can avoid harmful side effects in type 2 diabetes
September 22, 2018 - ALSAM Foundation invests additional $2 million for drug discovery and development projects
September 22, 2018 - Study findings may advance discussion of how to effectively curb human-wildlife conflict
September 22, 2018 - Dopamine neurons may involve in conditions ranging from Parkinson’s disease to schizophrenia
September 22, 2018 - Protein C and Protein S Tests: MedlinePlus Lab Test Information
September 22, 2018 - Obesity and diabetes—two reasons why we should be worried about the plastics that surround us
September 22, 2018 - Concern over fussy eating prompts parents to use non-responsive feeding practices
September 22, 2018 - Novel mathematical approach uncovers existence of unsuspected biological cycles
September 22, 2018 - Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub
September 22, 2018 - Scientists predict how well the body will fight lung cancer by analyzing immune cell shapes
September 22, 2018 - New outbreak of rare eye disease identified in contact lens wearers
September 22, 2018 - Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 22, 2018 - Research finds divide in dental health accessibility between city and regional areas
September 22, 2018 - Premature babies show better brain development when fed breast milk, finds study
September 22, 2018 - Novel system uses AI to detect abnormalities in fetal hearts
Rapid Onset Seen for Apremilast in PsA

Rapid Onset Seen for Apremilast in PsA

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized trial demonstrated that apremilast was efficacious in improving psoriatic arthritis symptoms in biologically naive patients.
  • The fact that apremilast, a phosphodiesterase inhibitor, is an oral agent may lead to broader adoption over IV agents.

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study.

After the second week of treatment, 16.4% of patients randomized to apremilast had achieved a 20% improvement on the criteria of the American College of Rheumatology (ACR20) compared with 6.4% of those receiving placebo (P=0.025), reported Peter Nash, MD, of the University of Queensland in Brisbane, Australia, and colleagues.

A statistically significant difference on ACR20 response rates also was seen between the apremilast and placebo groups at week 16, which was the study’s primary endpoint (38.2% versus 20.2%, P=0.004), the researchers reported online in Annals of the Rheumatic Diseases.

The efficacy of the phosphodiesterase 4 inhibitor apremilast among patients with psoriatic arthritis who had previous exposure to conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic agents was demonstrated in the three PALACE trials that were part of the drug’s clinical trial development program, with follow-up of up to 4 years. Concomitant conventional DMARD therapy was permitted in these trials.

The time to onset of the effect has not previously been assessed, however, and only one trial evaluated monotherapy.

Therefore, Nash and colleagues enrolled 219 patients who had previously received one conventional DMARD but no biologics in the study, named ACTIVE, assessing time to response and various other outcomes including effects on morning stiffness and enthesitis.

Patients had active psoriatic arthritis for at least 3 months, with three or more tender and swollen joints and C-reactive protein levels of 0.2 mg/dL or higher. Patients had to discontinue DMARDs but were allowed oral prednisone in dosages of 10 mg/day or less as well as nonsteroidal anti-inflammatory drugs or opioids.

Participants’ mean age was 49, and more than half were women. Almost all were white. The mean disease duration was 3.8 years; the mean number of swollen and tender joints were 10 and 18, respectively; and mean body mass index was 32 kg/m2.

Patients were randomized to receive oral apremilast, 30 mg twice daily, or placebo for the first 24 weeks. At week 16, those who had not had at least a 10% improvement in tender and joint counts were allowed early escape, and at week 24, all those still on placebo were switched to apremilast for the remainder of the 52-week study.

At week 2 — the first post-baseline assessment — significant mean changes from baseline other than ACR20 rates were seen on these outcomes for apremilast versus placebo:

  • Disease Activity Score in 28 joints (DAS28), -0.59 versus -0.31, P<0.05
  • Gladman Enthesitis Index, -1.1 versus -0.4, P<0.05
  • Health Assessment Questionnaire Disability Index (HAQl-DI), -0.13 versus -0.05, P<0.05

In addition, improvements in the severity of morning stiffness were reported at that time point for 42.7% versus 21.1% (P<0.005).

At week 16, significant percentage improvements were seen for swollen joints (-46.4% versus 4.2%, P<0.0001) and tender joints (-32.3% versus 2.5%, P<0.005), as well as in the duration of morning stiffness (-33.33 minutes versus no change, P<0.005).

Functional ability assessed on the HAQ-DI showed “clinically meaningful and significant improvements” at week 16 for apremilast versus placebo (-0.21 versus -0.06, P=0.023), and the mean changes in HAQ-DI scores met the minimal clinically important difference of -0.13 at weeks 2, 16, and 24.

Clinical benefits were sustained in the open-label phase through week 52 with apremilast treatment, at which time the percentage changes in swollen and tender joint counts were -77.5% and -70.4%, respectively.

During the blinded phase of the study, the most common adverse events were diarrhea, seen in 14.7% of the apremilast group and 11% of the placebo group, nasopharyngitis, nausea, and headache. Ten patients receiving apremilast and five on placebo discontinued during the first 24 weeks because of adverse events. Serious adverse events, none of which were considered treatment-related, were reported in 2.8% of the apremilast group and 4.6% of the placebo group during the blinded phase of the trial.

Four patients reported depression, but none were serious, and there were no cases of suicidal behavior or ideation, Nash and colleagues said.

Study limitations, they noted, included the fact that there was some baseline patient heterogeneity and there was a lack of imaging outcomes.

“Apremilast has a unique mechanism of action in modulating the expression of both pro-inflammatory and anti-inflammatory cytokines; in ACTIVE, no evidence of increased incidence of serious or opportunistic infections and no cases of active tuberculosis with 52-week apremilast exposure were observed,” the researchers said.

“These results support the use of apremilast monotherapy in biological-naive patients with psoriatic arthritis.”

The study was sponsored by Celgene Corporation.

The authors reported financial relationships with Celgene, Novartis, Roche, Schering-Plough, Bristol-Myers Squibb, Pfizer, UCB, AbbVie, Ardea Biosciences, AstraZeneca, Centocor, Galapagos, Genentech, GlaxoSmithKline, Human Genome Sciences, Janssen, Eli Lilly, Merck, Mesoblast, Novartis, Novo Nordisk, Sanofi-Aventis, Takeda, and Vertex Pharmaceuticals. Several co-authors are employees of Celgene.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-19T12:30:00-0500

Tagged with:

About author

Related Articles